CVI Holdings’s Novavax NVAX Stock Holding History

CVI Holdings’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-165,780	Closed	-$4.44M	–	50
2018 Q2	$4.44M	Buy	+165,780	New	+$5.6M	5.53%	4

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CVI Holdings's NVAX Position: Q3 2018 in Review

CVI Holdings sold out of Novavax (NVAX) in Q3 2018, closing a stake of 165,780 shares — an estimated $4.44M sold.

CVI Holdings first reported a position in NVAX in Q2 2018 and held it in 1 quarter. The position peaked at $4.44M in Q2 2018. 160 funds tracked by Wall St. Rank hold NVAX as of Q3 2018.

CVI Holdings reported no remaining Novavax position as of Q3 2018 after selling out during the quarter.
CVI Holdings sold 165,780 Novavax shares in Q3 2018, an estimated $4.44M.
CVI Holdings first reported a position in Novavax in Q2 2018 and held it in 1 quarter.
CVI Holdings's Novavax position peaked at $4.44M in Q2 2018.
160 funds tracked by Wall St. Rank held Novavax as of Q3 2018.

Based on CVI Holdings's 13F filing for Q3 2018, filed 14 Nov 2018.